Matthew Hawryluk Predictive Oncology Inc. (POAI) insider trading activity

Matthew Hawryluk is Director of Predictive Oncology Inc.. Currently has a direct ownership of 9,488 shares of POAI, which is worth approximately $7,875. The most recent transaction as insider was on Apr 05, 2024, when has been sold 2,368 shares (Common Stock) at a price of $0.0 per share, resulting in proceeds of $0. This information was disclosed in a Form 4 filing with the Securities and Exchange Commission (SEC).

Shares Held (Direct Ownership) 9.49K

0% 3M change

32.98% 12M change

Total Value Held $7,875

Matthew Hawryluk Transaction History

Date	Transaction	Value	Shares Traded	Shares Held
Apr 05 2024	BUY Grant, award, or other acquisition	-	2,368 Added 19.97%	9,488 Common Stock
Oct 02 2023	BUY Grant, award, or other acquisition	-	1,875 Added 20.81%	7,135 Common Stock
Jul 03 2023	BUY Grant, award, or other acquisition	-	2,675 Added 33.71%	5,260 Common Stock
Apr 03 2023	BUY Grant, award, or other acquisition	-	18,360 Added 26.21%	51,692 Common Stock
Jan 03 2023	BUY Grant, award, or other acquisition	-	19,570 Added 36.99%	33,332 Common Stock
Dec 01 2022	BUY Grant, award, or other acquisition	-	13,762 Added 50.0%	13,762 Common Stock

Also insider at

GRTS

Gritstone bio, Inc. Healthcare

EVP, CHIEF BUSINESS OFFICER